Grant: Master's Award: Canada Graduate Scholarships
University of Toronto
$17,500.00
Identifying the target of CD44 monoclonal antibodies in the amelioration of murine immune thrombocytopenia using human-CD44 and Cre recombinase mouse models
FY 2017-18
Summary
Intravenous immunoglobulin (IVIg) is the current treatment for a whole host of autoimmune and inflammatory disorders, including immune thrombocytopenia (ITP) which is a disorder characterized by low platelets. However, replacements for IVIg are necessary as it places a huge financial burden on the Canadian healthcare system, is limited in supply, and risks inducing hemolysis, coagulation and/or pathogenic transmission. A replacement currently being explored are antibodies targeting a glycoprotein known as CD44 which is expressed on most cells of the body. CD44 antibodies have shown anti-inflammatory activity in a variety of animal models of disease. However, very little is known about the cell(s) it targets in order to induce its therapeutic effects. Our lab has discovered that these antibodies do not require T and B cells to be functional, and interact with macrophages to exert some of its effects. Therefore, we hypothesize that these antibodies are likely inducing anti-inflammatory activity through interactions with innate immune cells such as macrophages and dendritic cells. My proposed study will be the first to identify the target of these antibodies using a transgenic mouse model expressing human CD44, in order to better model the activity of these antibodies in humans. I will selectively knock-out this protein in specific cell populations (such as macrophages and dendritic cells) and then treat these animals with human CD44 antibodies in order to assess the role of each cell type in ameliorating ITP. This study will fill a gap in current research by understanding the mechanisms of CD44 antibodies, and potentially replace IVIg with a therapeutic that eliminates the problems and risks currently associated with IVIg usage.
Department
Program
Master's Award: Canada Graduate Scholarships
Recipient
Location
Ontario, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database
As published
Id
386479
Name
Kaur Gurleen
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
Identifying the target of CD44 monoclonal antibodies in the amelioration of murine immune thrombocytopenia using human-CD44 and Cre recombinase mouse models
Programtype2
Studentship Programs
Orgnameinp2
University of Toronto
Cihramount2
$17,500
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Autoimmune Diseases; Cd44 Monoclonal Antibodies; Cre Recombinase Mice; Immune Thrombocytopenia; Immunotherapies; Innate Immune Cells; Intravenous Immunoglobulin; Platelets; Transgenic Mice
Abstract
Intravenous immunoglobulin (IVIg) is the current treatment for a whole host of autoimmune and inflammatory disorders, including immune thrombocytopenia (ITP) which is a disorder characterized by low platelets. However, replacements for IVIg are necessary as it places a huge financial burden on the Canadian healthcare system, is limited in supply, and risks inducing hemolysis, coagulation and/or pathogenic transmission. A replacement currently being explored are antibodies targeting a glycoprotein known as CD44 which is expressed on most cells of the body. CD44 antibodies have shown anti-inflammatory activity in a variety of animal models of disease. However, very little is known about the cell(s) it targets in order to induce its therapeutic effects. Our lab has discovered that these antibodies do not require T and B cells to be functional, and interact with macrophages to exert some of its effects. Therefore, we hypothesize that these antibodies are likely inducing anti-inflammatory activity through interactions with innate immune cells such as macrophages and dendritic cells. My proposed study will be the first to identify the target of these antibodies using a transgenic mouse model expressing human CD44, in order to better model the activity of these antibodies in humans. I will selectively knock-out this protein in specific cell populations (such as macrophages and dendritic cells) and then treat these animals with human CD44 antibodies in order to assess the role of each cell type in ameliorating ITP. This study will fill a gap in current research by understanding the mechanisms of CD44 antibodies, and potentially replace IVIg with a therapeutic that eliminates the problems and risks currently associated with IVIg usage.
Competitiondate
201712
Approvedterm2
1 yr 0 mth
Pinamesdelim
Kaur, Gurleen
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $17,500~ $0~